Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159861 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 267
- Enrollment target
NCT00159861 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 267 participants.
The verdict
NCT00159861, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 267 participants
- Enrollment target
Study Summary
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Interventions
- DRUG Sildenafil citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159861
The ClinicalTrials.gov registry entry for NCT00159861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil citrate is the first listed.
NCT00159861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00159861 about?
NCT00159861 is a clinical study titled "The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH". Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
What is the current status of trial NCT00159861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 267 participants. The study started on 2003-07. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00159861?
The interventions under investigation include: Sildenafil citrate (DRUG).
Who is sponsoring clinical trial NCT00159861?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.